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The sulfonylurea glibenclamide is widely used as an open-channel blocker of the CFTR chloride channel. Here, we used site-directed
mutagenesis to identify glibenclamide site of interaction: a positively charged residue K978, located in the cytoplasmic loop 3. Charge-
neutralizing mutations K978A, K978Q, K978S abolished the inhibition of forskolin-activated CFTR chloride current by glibenclamide but not by
CFTRinh-172. The charge-conservative mutation K978R did not alter glibenclamide sensitivity of CFTR current. Mutations of the neighbouring
R975 (R975A, R975S, R975Q) did not affect electrophysiological and pharmacological properties of CFTR. No alteration of halide selectivity
was observed with any of these CFTR mutant channels. This study identifies a novel potential inhibitor site within the CFTR molecule, and
suggests a novel role of cytoplasmic loop three, within the second transmembrane domain of CFTR protein. This work is the first to report on the
role of a residue in a cytoplasmic loop in the mechanism of action of the channel blocker glibenclamide.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cystic Fibrosis; CFTR chloride channel; Site of action; Glibenclamide; cytoplasmic loop three1. Introduction
The ATP-binding cassette (ABC) genes represent a large
family of transmembrane proteins widespread in archea,
bacteria and eukaryotes. ABC transporters bind ATP and
couple the energy released by ATP hydrolysis to transport of
wide variety of substances into or out of cells or organelles
[1–3]. The typical functional unit consists of a pair of ATP-
binding domains (Nucleotide Binding Domains), providing
necessary energy for solute transport, and two transmembrane
domains (TMD) delimiting a transport pathway. Among the
49 human ABC transporters [4], only CFTR (ABCC7) is an
ion channel: a chloride channel regulated by cyclic AMP and
phosphorylation [5]. CFTR belongs to the ABCC subfamily,Abbreviations: ABC, ATP binding cassette; CFTR, cystic fibrosis transmem-
brane conductance regulator; MRP, multidrug resistance-associated protein;
SUR, sulfonylurea receptor; CL, cytoplasmic loop; TMD, transmembrane
domain; Fsk, forskolin; Glib, glibenclamide; HEK, human embryonic kidney
⁎ Corresponding author.
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doi:10.1016/j.bbamem.2007.05.013the largest in the human ABC family, consisting in 12 full
members and one unusual truncated ABCC13 [6]. Each TMD
in ABC transporters is usually a bundle of six alpha-helices.
The number of helices within TMD of ABC transporters is
however variable. Six alpha-helices are generally found, but
10 helices are also frequently encountered. Moreover, in some
transporters such as SUR1, additional transmembrane
domains are found [1,2,4].
The sulfonylurea drug glibenclamide inhibits several ABC
proteins: P-glycoprotein [7], CFTR [8], SUR1,2 [9,10], MRP1–
5 [11–14]. Therefore, glibenclamide appears to be a general
inhibitor of ABC transporters, suggesting an interaction with
some conserved motif [7]. ABCC8 (SUR1) and ABCC9 (SUR2)
are high-affinity receptors for sulfonylureas [9] that, upon
binding tomultiple sites, promote the inhibition of the associated
K+ channel, Kir6.1 or Kir6.2 [15,16]. Although structurally not
yet well defined, the glibenclamide binding site of SUR1
appears to comprise cytoplasmic loop 3 (CL3), between TM5
and TM6, and CL8, between TM15 and TM16 [17–20].
Open channel blockers prevent chloride flow through the
channel by occluding the CFTR pore [21]. The organic
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complex mechanism involving multiple binding sites [22–
24]. Glibenclamide and chloride ions are presumed to
compete for common sites located within a large intracel-
lular vestibule that is part of the CFTR pore [23]. The
molecular determinants of the CFTR channel pore are not
fully known but TM1 and TM6 are proposed to be part of
the pore region [25,26]. The positively charged residues
K95 and R303 attract large anionic molecules (glibencla-
mide, DIDS, NPPB) into the wide inner vestibule where
they bind to block chloride permeation [27,28]. To our
knowledge, residues involved in the mechanism of action of
glibenclamide are all located into the pore of the CFTR
molecule.
In the CFTR protein, the CL3, between TM8 and TM9, is
speculated to be close to the intracellular mouth of the CFTR
pore [29]. Within CL3, we have now identified an octapeptide
sequence I972LNRFSKD979 relatively well conserved among
ABCC subfamily proteins (Supplemental Fig. 1), in which 8
proteins are glibenclamide sensitive (Fig. 1B). Could the
positively charged residues R975 and K978 be involved in the
glibenclamide sensitivity of CFTR? The present data indicate
that the charge of the side chain of K978, but not R975, isFig. 1. Lysine 978 of CFTR is located in a conserved sequence among ABC proteins su
positioned in the cytoplasmic loop (CL3 in CFTR) indicated by arrows. (B) Alignm
ABCC proteins. Classification of proteins is given. Starting and ending residue numb
the present work are boxed. Note that residue S1126 of human SUR1 corresponds trequired for CFTR inhibition by glibenclamide. The analogue
mutation in SUR1 was also studied (SUR1–S1127A). Despite
the sequence conservation, this mechanism could not be ex-
tended to SUR1 protein.
2. Experimental procedures
2.1. Plasmid constructs
Mutations were introduced by PCR using oligonucleotide-directed
mutagenesis system (Quick ChangeXL Site-Directed Mutagenesis Kit,
Stratagene) into (1) the pEGFP-CFTRwt (human cDNA) [30], (2)
pcDNA3-SUR1 (hamster cDNA) [31]. The presence of mutations was
confirmed by dideoxynucleotide sequencing on both strands. Other details
appear elsewhere [32].
2.2. Functional analysis of ABCC proteins
For CFTR chloride channels, experiments were carried out on HEK-293
cells transiently transfected with wild-type or mutant EGFP-CFTR, at room
temperature (20–25 °C). Experiments using broken-patch whole cell mode were
performed as previously described [33]. The holding potential was −40 mV.
Current/voltage (I/V) relationships were built by clamping the membrane
potential to −40 mV and by pulses from −100 mV to +100 mV in 20 mV
increments. The intrapipette solution contained (in mM): 113 L-aspartic acid,
113 CsOH, 27 CsCl, 1 NaCl, 1 MgCl2, 1 EGTA, 3 MgATP (ex-temporane),bfamily C. (A) Predicted topologies of CFTR and SUR1. Conserved sequence is
ent of the cytoplasmic loop sequences of all functional members of the human
ers are specified. Key positions are indicated by arrows and mutated residues in
o residue S1127 of hamster SUR1 experimentally tested.
2440 P. Melin et al. / Biochimica et Biophysica Acta 1768 (2007) 2438–244610 TES, titrated with CsOH to pH 7.2, 285±5 mOsmol. The external bath
solution contained (in mM): 145 NaCl, 4 CsCl, 1 CaCl2, 1 MgCl2, 10 glucose,
and 10 TES, titrated with NaOH to pH 7.4, 315±5 mOsmol. Following
membrane rupture, CFTR chloride channels were activated by exposure
extracellular side to Fsk 10 μM. After stable activation, CFTR inhibitors were
added to the patch-clamp chamber from solutions made up fresh every 3 h in
normal extracellular solution (pH checked). To prevent molecules photode-
gradation, experiments were performed in the dark. To quantify current
inhibition, I/Io ratios were calculated, I being the current density in the
presence of blocker (glibenclamide or CFTRinh-172) and Io the unblocked
current density (with Fsk). To compare the relative effect of glibenclamide on
wild type or mutants CFTR channels, the Kd was determined according to the
equation Kd=[B] / ((1 / (I− I0))−1), with [B], concentration of blocker [27]. To
measure the reversal potential of chloride currents, equivalent amount of NaCl
was replaced by NaBr or NaI in the extracellular solution. Reversal potential
was measured after stable activation of channels by Fsk 10 μM. The ABCC8
KATP channel activity was characterized by the patch-clamp technique in the
excised inside-out configuration on mRNA-injected Xenopus laevis oocytes as
previously described [34].
2.3. Statistics
Results are expressed as means±S.E.M. of n experiments. Sets of data were
compared with a Student's t test. Differences were considered statistically
significant when Pb0.05. ns: non significant difference, *Pb0.05, **Pb0.01,Fig. 2. Effect of K978S mutation on the whole cell EGFP–CFTR chloride currents.
EGFP–CFTR channels wild-type (left) and charge neutralizing mutant K978S (rig
100 μM (B), and sub-sequential addition of CFTRinh-172 10 μM (C). (D) Correspon
n=10 for K978S).***Pb0.001. All statistical tests were performed using GraphPad Prism 4.0 for
Windows (Graphpad Software).
2.4. Chemicals
All chemicals were from Sigma Chemicals except forskolin (PKC
Pharmaceuticals) and CFTRinh-172 (Calbiochem). Stock solutions of glib-
enclamide and forskolin: 100 mM, CFTRinh-172: 10 mM, were prepared in
DMSO.
3. Results
3.1. Effects of mutagenesis of K978 on the glibenclamide
inhibition of CFTR
Positive amino acids of the TM1 of CFTR play an impor-
tant role in attracting both permeant and blocking anions into
the CFTR channel pore [27]. We investigated the role of the
charged residue K978 in the sequence ILNRFSKD of CL3
(Fig. 1B) described as a region physically close to the pore
[29] and examined the interaction of glibenclamide with
mutated EGFP-CFTR channels: K978A, K978Q, K978R,Representative traces of global currents recorded on HEK-293 transfected with
ht) are shown in presence of Fsk 10 μM (A), after perfusion of glibenclamide
ding current–voltage relationships normalized by cell capacitance (n=6 for wt,
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of CFTR does not alter CFTR chloride function or CFTR
pharmacology [30]. With HEK-293 cells transiently expres-
sing EGFP-CFTR-wt proteins, stimulated with Fsk 10 µM,
the whole-cell chloride current increased linearly with voltage
(Fig. 2A, D, left). Similar effects in the presence of Fsk were
recorded with cells expressing K978A, K978Q, K978R and
K978S mutants CFTR. Representative chloride currents
recorded with K978S are shown in Fig. 2A (right). Consistent
with previous works, extracellular perfusion with 100 μM
glibenclamide produced a reduction in current with a slight
outward rectification of the CFTR-wt I/V relationship (Fig. 2B
left). Interestingly, perfusion of glibenclamide did not induce
inhibition of forskolin-activated chloride currents in EGFP–
CFTR–K978S expressing cells (Fig. 2B right). The difference
between the two I/V curves in the presence of Fsk versus
Fsk+Glib, at all voltages for K978S channels, was not
statistically different (PN0.05) using analysis of variance
followed by a Bonferroni post hoc test (Fig. 2D right).
Because voltage might alter the gating of CFTR chloride
channel [35] and CFTR glibenclamide inhibition is voltage
dependent [8], inhibition was evaluated at hyperpolarization
(−100 mV) and depolarization (+40 mV) of HEK transfected
membrane cells. The current amplitude recorded at +40 mV
revealed a N85% block in presence of Fsk+Glib for CFTR-
wt, N98% block at −100 mV (Fig. 3A, left). Further addition
of CFTRinh-172 had no supplementary inhibitor actionFig. 3. Mutagenesis of positively charged K978 prevents blockage of CFTR chann
densities (pA/pF), recorded at −100 mV and +40 mV, in various conditions (indica
CFTR–K978S (right). Data are mean±S.E.M. of n experiments (n=7 for wt, n=10 f
+40 mVand −40 mV, normalized by cell capacitance, in presence of various agonists
CFTR–K978S channels were inhibited by CFTRinh-172 but not by glibenclamide.(PN0.05). In contrast, K978S activity, after glibenclamide
application, was fully inhibited by CFTRinh-172 (Fig. 3A,
right). From continuous whole cell recordings with voltage
steps between −40 mV and +40 mV, we estimated that full
inhibition of CFTR-wt current by glibenclamide was achieved
in ∼250 s (Fig. 3B left) whereas K978S activity remained
remarkably stable as long as the sulfonylurea was present
(Fig. 3B right). The inhibition by CFTRinh-172 of CFTR–
K978S was, on the contrary, almost immediate and very rapid
as illustrated at the end of the recording, Fig. 3B (right). Thus,
the charge neutralizing mutant K978S is resistant to
glibenclamide block, but remains sensitive to the blocker
CFTRinh-172. To investigate the role of the charge of the side
chain of K978 in glibenclamide resistance, different amino
acid substitutions were examined: K978A, K978Q, K978R.
Because glibenclamide inhibits CFTR channels in a voltage-
dependent manner [8], more pronounced inhibition occurs at
negative voltages. Fig. 4A presents the ratio Iglib/Ifsk,
recorded at −100 mV, with 100 μM glibenclamide, for
K978A, K978Q, K978R, K978S channels compared to
CFTR-wt. These results strongly suggest that the side chain
charge at position 978 is important for glibenclamide
inhibition of CFTR. Indeed, the ratio at −100 mV for the
charge conservative mutant K978R (0.17± 0.04, n=4) was
not significantly different from that of CFTR-wt. However,
for K978S channels, the ratio at this voltage was significantly
(Pb0.001) increased to 0.81±0.04 (n=4). Other chargeels by glibenclamide but not by CFTRinh-172. (A) Summary of mean current
ted on graph) for HEK cells transfected with EGFP–CFTR-wt (left) or EGFP–
or K978S). (B) Representative currents amplitude time course recorded between
(Fsk 10 μM, Fsk+Glib 100 μM, Fsk+ CFTRinh-172 10 μM). Note that EGFP–
Fig. 4. The charge of the side chain of the amino acid 978 is involved in glibenclamide inhibition of CFTR channels. (A), Mean ratio (±S.E.M.) of currents recorded
with glibenclamide (I, Fsk 10 μM+Glib 100 μM) on unblocked currents (Io, Fsk), at a membrane potential of −100 mV, from different EGFP–CFTRmutants of K978.
(B) Examples of time course of current densities (between +40 mVand −40 mV) from the charge neutralizing mutants CFTR–K978Q (■) and CFTR–K978A (◯) in
presence of Fsk 10 μM, and Fsk+Glib 100 μM, and Fsk+CFTRinh-172 10 μM. (C), Mean ratio±S.E.M. of currents recorded, at −100 mV, with blocker CFTRinh-172
(Fsk 10 μM+CFTRinh-172 10 μM) on unblocked currents (Fsk), at −100 mV, from different mutants of K978. (D) Mean Kd±S.E.M. (in µM) of CFTR current block
by glibenclamide with different mutants of K978 vs. wt-CFTR.
2442 P. Melin et al. / Biochimica et Biophysica Acta 1768 (2007) 2438–2446neutralizing mutations (K978A, K978Q) rendered channels
insensitive to inhibition by glibenclamide as demonstrated by
the time course of current recorded at +40 mV (Fig. 4B). By
contrast, CFTRinh-172 fully inhibited mutant channels with the
same efficiency as CFTR-wt (Fig. 4C). Sensitivity to glib-
enclamide depends on charge of the side chain of the residue 978
(Fig. 4D). The apparent Kd at −100 mV was not affected by the
charge conservative mutation (b25 μM), but was significantly
increased in charge neutralizing mutation (N250 μM). Thus, the
charge of the side chain of residue 978 is crucial for CFTR
sensitivity to glibenclamide but has no incidence on the
inhibition by CFTRinh-172.
3.2. Effects of mutagenesis of arginine 975 on the
glibenclamide inhibition of CFTR
We studied the effect of substitutions of R975, another
positively charged residue located in the conserved sequence
ILNRFSKD (Fig. 1B). After expression in HEK-293 cells, the
whole-cell chloride currents recorded with charge neutralizing
mutants CFTR–R975A, R975Q and R975S (Fig. 5) showed
similar electrophysiological properties as CFTR-wt: linear
activation with Fsk, inhibition by glibenclamide and by
CFTRinh-172. Thus, R975 of CL3 has no apparent role in
pharmacological inhibition of CFTR.3.3. Effects of mutagenesis of K978 and R975 on the halide
selectivity of CFTR
Several sites of electrostatic interaction with chloride ions
have been identified, among them positively charged lysine and
arginine located in the TMs of CFTR [36]. However, CL3 is
apparently not an integral part of the CFTR pore [29].
Nevertheless, the halide selectivity sequence was examined
for the CFTR mutants and compared to CFTR-wt. For K978S
channels, refractory to glibenclamide, the experimental reversal
potentials were −43±1.5 mV (n=4) for bromide, −42.5±
1.5 mV (n=4) for chloride, and −29±5 mV (n=3) for iodide.
The selectivity sequence of CFTR currents was unaffected by
the replacement of the K978 or R975 (data not shown). So, the
charge of K978 and R975 of CL3 has no influence on the anion
permeation sequence.
3.4. Role of serine 1127 in the glibenclamide sensitivity of
SUR1
SUR1 and SUR2 bind glibenclamide with widely
different affinities, ∼0.6 nM and ∼300 nM, respectively
[37]. In SUR1, the residue aligned to the critical K978 of
CFTR is a serine (S1127) while it is an alanine in SUR2
(Fig. 1B). We reasoned that if this residue also controls
Fig. 5. Mutagenesis of R975 does not affect CFTR chloride channels properties. Original currents recorded on HEK-293 transfected with EGFP–CFTR–R975Awith
Fsk 10 μ M (A), Fsk+Glib 100 μM (B), and Fsk+CFTRinh-172 10 μM (C). (D) Representative time course of current densities from the charge neutralizing mutant
EGFP–CFTR–R975A in presence of Fsk 10 μM, Fsk+Glib 100 μM, Fsk+CFTRinh-172 10 μM. (E) Current–voltage relationships normalized by cell capacitance
recorded from R975A (n=11), R975S (n=7) and R975Q (n=4) EGFP–CFTR channels in presence of agonists. Data are mean±S.E.M. of n experiments.
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alanine found in SUR2 might reduce glibenclamide
sensitivity. The effect the mutation SUR1–S1127A was
evaluated by comparing glibenclamide block of wild-type
and mutated KATP channels after expression in Xenopus
oocytes. However, application of 100 nM glibenclamide
blocked both the wild-type (85±13%, n=11) and the
mutated channel (95±4%, n=7) (Fig. 6). The half inhibition
times of wild-type and S1127A were not statistically
different (4.7±2.2 s, n=7 and 6.4±4 s, n=10, respectively).
Thus, mutation on the SUR1 subunit of the ILNRFSSD
sequence into ILNRFSAD within the CL7, between TM13
and TM14, does not alter the sensitivity to glibenclamide of
KATP channels.
4. Discussion
The present report showed that several substitutions of
lysine 978 of CFTR alter the inhibitory response of CFTR
channels to the anionic glibenclamide but not to the
uncharged inhibitor CFTRinh-172. This was the case for the
mutations that neutralized the charge of the side chain of the
residue 978 (K978A, K978Q, K978S). Charge neutralizing
mutations decreased CFTR channel sensitivity to glibencla-
mide while they did not affect sensitivity to CFTRinh-172. Incontrast, substitution of lysine 978 with another positively
charged residue (K978R) had no incidence on glibenclamide
sensitivity of CFTR channels. This charge conservative
mutant shared the same properties of inhibition as CFTR-
wt. We conclude that the nature of the residue 978 in CFTR
is not crucial, but the positive charge of the side chain at this
location is involved into glibenclamide inhibition. These
results would be consistent with electrostatically attractive
interaction between the positive charge of K978 and the
negative charge of glibenclamide. Therefore our study
suggests a novel role for the CL3 of the CFTR protein
implicated as a potential pharmacological inhibitory site. As
K978 is involved in the site of action of the open channel
blocker glibenclamide, the CL3 is presumed to be close to the
pore. This is in agreement with the recent elucidation of the
crystal structure of a bacterial ABC transporter (Sav1866)
from Staphylococcus aureus [38]. In this context, it is also
important to note that the structure of the bacterial Sav1866
transporter is made of two transmembrane domains with six
helices, like CFTR [38].
A current view of the CFTR pore (for review [36])
involves the first and the sixth transmembrane regions of the
protein [26]. Some positively charged amino acids act by
attracting chloride ions into the pore structure. For example,
K95 in TM1 [27] and R334 in TM6 [39,40] create
Fig. 6. Mutation S1127A on SUR1 subunit does not alter the glibenclamide sensitivity of KATP channels. (A) Average currents for SUR1+Kir6.2 and SUR1
S1127A+Kir6.2 measured in 100 μM ADP before (dark bars) or after (white bars) application of Glibenclamide (100 nM). Currents were normalized to the current
measured in 0 ATP before application of nucleotides. Error bars represent S.E.M. and numbers of repetition are noted above the bars. (B) Representative currents
recorded in inside-out patches from Xenopus oocytes expressing SUR1+Kir6.2 and S1127A–SUR1+Kir6.2 (C). Glibenclamide (100 nM) was applied in the
presence of 100 μM ADP.
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study shows that the positively charged R303 and R352,
located near the intracellular ends of the TM5 and TM6
regions, regulate anion conduction through the CFTR pore
[25]. K95 and R303 also attract large blocker molecules, such
as glibenclamide, into the CFTR pore [27,28]. In the CL3
region, we showed that R975 and K978, on the contrary, do
not influence the chloride permeation. Thus, our results
highlight the role of lysine 978 only in glibenclamide
interaction with CFTR protein.
SUR1, another ABCC protein, has considerable sequence
similarity with CFTR and it binds glibenclamide, though
with a much greater affinity. It is interesting to note that the
binding affinity for SUR of glibenclamide is favoured by the
anionic group of hypoglycaemic sulfonylureas and acidic
analogues [41]. S1127 of SUR1 matches K978 of CFTR anda single serine (S1237) was identified as molecular site
involved in the binding of tolbutamide and glibenclamide
[17]. We tested the involvement of this residue in
glibenclamide efficiency by mutating it to the aligned residue
of SUR2, a SUR isoform with a lower affinity for
glibenclamide than SUR1. In absence of ADP, blocking
affinity in inside-out patches EC50=4.2 nM for SUR1 and
EC50=27 nM for SUR2A [42]. However, they show that
with 100 μM ADP, 100 nM of glibenclamide blocks ∼90%
SUR1/Kir6.2 and N∼10% SUR2A/Kir6.2. We have also
observed similar differences in our model. However, the
mutation S1127A did not reduce glibenclamide block of
KATP channels, implying a lesser role of this residue than in
CFTR. The glibenclamide binding site of SUR1 is not yet
well defined. It appears to be made up of multiple regions
including the TM5–TM6 and TM15–TM16 cytoplasmic
2445P. Melin et al. / Biochimica et Biophysica Acta 1768 (2007) 2438–2446loops [19,20,43], equivalent to the N-terminal loop and CL4
of CFTR.
In conclusion, we propose a model in which the positive
charge of lysine 978 within the cytoplasmic loop 3 of CFTR
could act as a first bait to drive glibenclamide (possibly through
electrostatic interactions) into the pore. Glibenclamide could
then be stabilized by additional positively charged amino-acids
(like K95 and R303) located in the depth of the channel pore
[27,28]. Our study also suggests a position close to the CFTR
pore for cytoplasmic loop 3 and especially for the side chain of
residue 978. Finally, whether the inhibition by glibenclamide of
other ABCC members, such as MRP1–5 (Fig. 1), is also
dependent on the corresponding sequence ILNRFSKD is not
known but will be the subject of future studies.
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